A native of South Florida, Dr. Mario del Cid joined the Retina Group of Florida after completing his fellowship in diseases and surgery of the retina and vitreous at the Cincinnati Eye Institute and the University of Cincinnati in Ohio.
Dr. del Cid received his Bachelor of Arts degree, Magna Cum Laude, in Psychology from Florida International University. He earned his Medical Degree from Tulane University. He then completed his ophthalmology residency from the University of Texas Health Science Center in San Antonio, where he was awarded the Mary Bass Boenker Scholar Award, named Resident of the Year, and appointed Chief Resident during his final year.
Dr. del Cid has a research interest in the use of non-steroidal therapeutics in ophthalmology and has presented his research at the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Retina Society and the American Society of Retina Specialists. He has multiple publications in various peer-reviewed journals. Dr. del Cid is a member of the American Society of Retina Specialists, the Broward County Ophthalmological Society, and the American Academy of Ophthalmology. Dr. del Cid is board-certified by the American Board of Ophthalmology and is also a Clinical Assistant Professor in the Department of Ophthalmology at Herbert Wertheim College of Medicine, Florida International University.
In his spare time, Dr. del Cid enjoys spending time with his wife and family. He enjoys biking, golfing, and marathon running. He is fluent in both English and Spanish.
Fellowship Jul 2010 – Jun 2012
Cincinnati Eye Institute/University of Cincinnati
Residency Jul 2007 – Jun 2010
Department of Ophthalmology
University of Texas Health Science Center San Antonio
San Antonio, TX
Internship Jul 2006 – Jun 2007
Department of Internal Medicine
Ochsner Clinic Foundation
New Orleans, LA
Medical Degree Aug 2002 – Jun 2006
Tulane University School of Medicine
New Orleans, LA
Bachelor of Arts in Psychology (Magna Cum Laude) Sep 1997 – Dec 2001
Florida International University
Imperial Point Medical Center, Broward Health, Ft. Lauderdale, FL 2012 – Present
Broward County Ophthalmological Society 2012 – Present American Society of Retina Specialists 2011 – Present American Academy of Ophthalmology 2007 – Present American Society of Cataract and Refractive Surgeons 2007 – 2010 Texas Medical Association 2007 – 2010
Mary Bass Boenker Scholar Award for Excellence in Research 2010 Resident of the Year Award 2010 Dr. Mark Gallardo Academic Excellence Award for Highest OKAP Score 2008 -2010 Golden Key National Honor Society 2001 Alpha Epsilon Delta 2001 Phi Kappa Phi 2001 Phi Beta Kappa 2001 Graduate of the FIU Honors College 2001
1. del Cid MR, Trichopoulos N, Liang Y. Factors Associated with Repeat Vitreous Hemorrhage Following Vitrectomy for Diabetic Vitreous Hemorrhage. Investigative Ophthalmology and Visual Science. 2009; 50: ARVO E-Abstract 6075. Poster at ARVO, Ft. Lauderdale, FL and presentation at Alamo City Ophthalmology Clinical Conference, San Antonio, TX, 2009.
2. Singer MA, del Cid MR. Are Topical Non-steroidals Safe for Long Term Use? Poster, American Academy of Ophthalmology Annual Meeting, San Francisco, CA, 2009.
3. Singer MA, del Cid MR. Unknown Case: Ocular Castleman’s Disease. Retina Congress Annual Meeting, New York, NY, 2009.
4. del Cid MR. Corneal Melts Associated with the Use of Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Review of the Literature. Alamo City Ophthalmology Clinical Conference, San Antonio, TX, 2010.
5. O’Connor P, del Cid MR. Perioperative Corneal Abrasion Prevention Project: UTHSCSA Department of Ophthalmology Quality Improvement Project, San Antonio, TX, 2010.
6. del Cid MR, Singer MA, Bell D. Topical Nonsteroidal Therapy for the Treatment of Central Serous Chorioretinopathy. Invstigative Ophthalmology and Visual Science. 2010: ARVO E-Abstract 3311. Poster at ARVO, Ft. Lauderdale, FL, 2010.
7. del Cid MR, Miller DM. Autoflourescence Findings in Presumed Ocular Histoplasmosis Syndrome. University of Cincinnati Annual Ophthalmologic Conference and Research Symposium, Cincinnati, OH, 2011
8. del Cid MR, Riemann CD. 27-Gauge Pars Plana Vitrectomy. University of Cincinnati Annual Ophthalmologic and Research Symposium, Cincinnati, OH, 2012 and Retina Society Meeting, Washington DC, 2012.
1. del Cid MR, Anand RG, Sossaman GN, Shah SB. Cardiac Sarcoidosis: A Case Report and Review of the Literature. The Journal of the Louisiana State Medical Society, 2008. 160 (3), 155-9.
2. Singer MA, del Cid MR, Stelton C, Boord T. Pars Plana Capsulotomy in a Patient with an Implantable Miniature Telescope for AMD. Archives of Ophthalmology, 2010. 128 (8), 1065-1067.
3. Singer MA, del Cid MR, Luth J, Porbandarwalla SS, Herro A, Pollard J, Woods P. Incidence of Corneal Melt in Clinical Practice: Our Experience Versus a Meta-Analysis of the Literature. Clinical and Experimental Ophthalmology, 2011. S1, 1-6.
1. Sub-Investigator – Protocol FVF4579g: A phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0 mg Ranibizumab administered monthly or on an as-needed (PRN) in patients with subfoveal neovascular age-related macular degeneration. Sponsored by Genentech, July 2009 to June 2012.
2. Sub-Investigator – Protocol FVF4870g: A phase IB/II, multicenter, randomized, single-masked, sham injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month to patients with geographic atrophy. Sponsored by Genentech. October 2009 to June 2012.
3. Sub-Investigator. Controlled, double-masked, randomized, multicenter study to evaluate XXXXX as a treatment of exudative AMD (RACE, C-09-067), Alcon Research Ltd, 2010 – 2011.
4. Sub-Investigator. A phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5mg and 2.0mg ranibizumab administered monthly or on an as-needed basis (prn) in patients with subfoveal neovascular age-related macular degeneration (HARBOR, FVF 4579g), Genentech Inc., 2010 – June 2012.
5. Sub-Investigator. An open label, long-term, safety and tolerability extension study of intravitreal VEGF trap-eye in neovascular age-related macular degeneration (VGFT-OD-0910), Regeneron Pharmaceuticals, Inc., 2010 – June 2012.
6. Sub-Investigator. A phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous injections of XXXXX given in combination with Lucentis in subjects with neovascular age-related macular degeneration (OPH1001), Ophthotech Corp., 2010 – June 2012.
7. Sub-Investigator. A randomized, double masked, active controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degenereation (VGFT-OD-0605), Regeneron Pharmaceuticals, Inc., 2010 – June 2012.
8. Sub-Investigator – Protocol CRFB002A2407: A 16 week evaluation of the Novartis Health Management Tool in assessing self-test visual function in patients with AMD treated with Lucentis. Sponsored by Novartis. May 2011 to June 2012.
9. Sub-Investigator – Protocol C-09-067: Controlled, double-masked, randomized, multicenter study to evaluate AL-78898A as a treatment of Exudative AMD. Sponsored by Alcon. May 2011 to June 2012.
10. Sub-Investigator – DRCR.net protocol T: A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema. September 2012 to Present.
11. Sub-Investigator – Optos study. September 2012 to Present.